Profound Medical, Telix Link PSMA-PET and TULSA-PRO in Education Pact
Image
Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.
The agreement sets a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, complement Profound's MRI-guided TULSA-PRO platform. The companies plan to cover the full prostate care continuum.